IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August:

• 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors.

• Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, as well as participate in one-on-one meetings. To join the presentation, please visit the webcast available online at: https://sidoti.zoom.us/webinar/register/WN_rqHxQLa-SP-7yjOy-Qditw

For additional details about the conferences or to schedule a one-on-one meeting with Oncocyte’s management team, please contact your Needham or Sidoti representative, or reach out directly to the company’s IR contact, jramson@pcgadvisory.com.

About Oncocyte
Oncocyte is a molecular diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/

VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/

GraftAssure™ - https://oncocyte.com/graftassure/

DetermaIO™ - https://oncocyte.com/determa-io/

DetermaCNI™ - https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:
Jeff Ramson

PCG Advisory

(646) 863-6893
jramson@pcgadvisory.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.